MiNK Therapeutics
Nasdaq INKT · New York, NY
Works in Cardiovascular · Hematology · Immunology · Infectious disease · Oncology · Respiratory
MiNK Therapeutics is a clinical trial sponsor based in New York, NY, listed as Nasdaq INKT. It has 1 active clinical trial with 90 planned participants, across 6 therapeutic areas. Since 2021 it has completed 3 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq INKT
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about MiNK Therapeutics
MiNK Therapeutics is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 90 planned participants, in Cardiovascular, Hematology, Immunology, Infectious disease and other areas. Since 2021 it has completed 3 trials and stopped 0 early.
MiNK Therapeutics is based in New York, NY and is listed as Nasdaq INKT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with MiNK Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-06-26.
Approve Suite is not affiliated with MiNK Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.